Developing New Treatment Approaches for Solid Tumor Cancers

T-cell receptor (TCR) T-cell therapy takes a personalized approach to cancer treatment by engineering a patient’s own T cells to recognize and attack cancer cells. Given as a one-time, single infusion, these cell therapies have the potential to improve the treatment experience for some of the most difficult to treat solid tumor cancers.

Navigating The Complexities and Challenges of Solid Tumor Cancers

While chemotherapy, radiation, surgery, and targeted therapies play pivotal roles in combating solid tumor cancers, they are not always effective, leaving patients in need of second-line therapies.ⁱ In addition, the side effects can be incredibly painful – sometimes as debilitating as the cancer itself.ⁱⁱ Unlike liquid tumors, where cancer cells are made of single cell types with the same antigen, solid tumors present uniquely difficult challenges due to their complexity. They are made up of diverse cell types with different mutations, expressing a myriad of antigens.ⁱⁱⁱ These drastic variations often limit the success of existing treatment therapies.^iv With solid tumors accounting for nearly 90 percent of all cancer, the need for novel treatment options is more important than ever.ⁱⁱⁱ

Exploring TCR T-cell therapy for Solid Tumor Cancers

Adaptimmune, a cell therapy company, has multiple cell therapies in clinical trials for solid tumors, such as synovial sarcoma, myxoid/round cell liposarcoma (MRCLS), ovarian cancer, and head and neck cancers. These investigational therapies are engineered from a patient’s own cells, targeting very specific antigens in the body, and each delivered in a single dose. As exciting as the science is, the company is driven by the potential impact on patients and families.

“At Adaptimmune, our commitment is to design, develop, and deliver cell therapies with the goal of transforming the lives of people with cancer,” said Dennis Williams, Pharm.D., senior vice president of late-stage development at Adaptimmune.

For more information, we invite you to visit https://www.adaptimmune.com.

About Adaptimmune

Adaptimmune is a fully-integrated cell therapy company working to redefine how cancer is treated. With its unique engineered T-cell receptor (TCR) platform, the company is developing personalized medicines designed to target and combat difficult-to-treat solid tumor cancers and to improve the patient’s cancer treatment experience. The safety and efficacy of TCR T-cell therapies have not been established.

ⁱ Zhang, T. (2024). Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances. Journal of Controlled Release, 368, 372-296.

ⁱⁱ Clevland Clinic. “Chemotherapy and Radiation Side Effects.” https://my.clevelandclinic.org/health/articles/10257-chemotherapy-side-effects. Accessed June 6, 2024.

ⁱⁱⁱ Weir, K. “Engineering the Immune System to Tackle Solid Tumors.” Penn Medicine. https://www.pennmedicine.org/news/publications-and-special-projects/penn-medicine-magazine/immune-health/engineering-the-immune-system-to-tackle-solid-tumors. Accessed June 5, 2024.

^iv Secondino, S. (2023) Clinical Trials of Cellular Therapies in Solid Tumors. Cancers 2023, 15, 3667.

Cancer Today magazine is free to cancer patients, survivors and caregivers who live in the U.S. Subscribe here to receive four issues per year.